Sanofi Q1 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Pharmaceuticals | Market Cap: ₹1.1L Cr
- For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, continuing profitable growth over at least 5 years. - In 2026, Sanofi expects sales to grow by a high single-digit percentage.
From Sanofi's Q1 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹44.29
Market Cap
₹1.1L Cr
P/E Ratio
19.2
Revenue Rank
Margin Rank
How does Sanofi rank in Pharmaceuticals?
Compare Sanofi against every Pharmaceuticals company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 4- →For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, continuing profitable growth over at least 5 years. (Page 16)
- →Long-term ambition includes pursuing earnings growth into the next decade based on pipeline and external growth opportunities. (Page 16)
- →Vaccine sales are expected to slightly decline in 2026 amid ongoing portfolio optimization. (Page 3)
- →Strong growth drivers include expansion of Dupixent with multiple indications and new medicine launches like Qfitlia, Wayrilz, and Nuvaxovid. (Pages 2, 16)
- →Pipeline advancements with promising assets (e.g., amlitelimab, gene therapies), plus business development firepower of €14-15 billion for strategic acquisitions, primarily focused on Phase I and II assets. (Pages 14, 3)
- →Expectation of continued volume growth, especially in immunology and vaccine expansions outside the U.S. (Page 6)
📈 Profitability & Margins
Rank 3- →In 2026, Sanofi expects sales to grow by a high single-digit percentage.
- →Business EPS (Earnings Per Share) is anticipated to grow slightly faster than sales in 2026.
- →Profitable growth is projected to continue for at least 5 years from 2025 onwards.
- →The company aims to pursue earnings growth into the next decade, supported by its pipeline and external growth opportunities.
- →For 2026, the outlook includes:
- → - Sales growth close to 2025’s performance (9.9% in 2025).
- → - Operating income to include around EUR 500 million of capital gains from disposals.
- → - Stable effective tax rate.
- →Sanofi targets sustainable free cash flow of at least 20% of net sales in the medium term, up from 18.5% in 2025.
- →The company plans disciplined capital allocation aimed at long-term returns rather than short-term growth chasing.
🏗️ Capital Expenditure Plans
Yes- →In 2025, Sanofi significantly increased organic growth investments in R&D, commercial capabilities, CapEx, and digital transformation to fuel current and future growth.
- →They deployed proceeds from the Opella divestment into strategic acquisitions such as Blueprint, Vicebio, Dren Bio DR-0201, and Vigil to accelerate transformation.
- →Moderate increase expected in underlying R&D expenses for 2026, alongside added placeholder for potential future acquisitions, particularly Phase I and II assets.
- →Sales and marketing expenses will rise in 2026 to support growth and launches.
- →Stable G&A expenses targeted in 2026.
- →A EUR 1 billion share buyback program is planned for 2026, continuing capital allocation policy focused on sustainable value creation and shareholder returns while investing in long-term growth opportunities.
- →Continued portfolio optimization via divestments expected, reducing sales by approx. EUR 200 million in 2026.
- →Operating income to include around EUR 500 million of capital gains from disposals in 2026.
💰 Fundraising & Capital Structure
No- →Sanofi ended 2025 with a strong capital structure and low net debt of EUR 11 billion.
- →Maintained a conservative net debt-to-EBITDA ratio of 0.8x, supporting financial flexibility.
- →The company has significant financial flexibility for future external growth opportunities while maintaining its AA rating.
- →No specific mentions of new fundraising through debt or equity in 2026; instead, focus on disciplined capital allocation and use of existing financial resources.
- →Planned to execute a EUR 1 billion share buyback program in 2026, continuing shareholder returns.
- →Increased R&D investments and placeholder for potential future acquisitions, funded through existing resources and cash flow.
- →Emphasis is on disciplined and strategic use of capital without explicit plans for new debt or equity issuance announced.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Pharmaceuticals this season
- Haleon plc (Q1 FY26)
Haleon plc Q1 FY26 quarterly results analysis. Organic sales growth guidance for 2026 is 3% to 5%, signaling some sequential acceleration from 3% in 2025. Marke
- Takeda Pharmaceutical Company Limited (Q1 FY26)
Takeda Pharmaceutical Company Limited Q1 FY26 quarterly results analysis. Growth in plasma-derived therapies (PDT) expected to be mid-single-digit growth for th
- Novo Nordisk A/S (Q1 FY26)
Novo Nordisk A/S Q1 FY26 quarterly results analysis. 2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at consta
- Novartis AG (Q1 FY26)
Novartis AG Q1 FY26 quarterly results analysis. Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competiti
Frequently Asked Questions
What were Sanofi Q1 FY26 results?
- For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, continuing profitable growth over at least 5 years. - In 2026, Sanofi expects sales to grow by a high single-digit percentage.
What is Sanofi share price analysis?
Sanofi currently shows a neutral. The stock trades at a P/E of 19.2 with a market cap of $108,017. Investors should review the full earnings analysis for detailed insights.
Is Sanofi planning capital expenditure?
- In 2025, Sanofi significantly increased organic growth investments in R&D, commercial capabilities, CapEx, and digital transformation to fuel current and future growth.
Keep Sanofi on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.